. Author manuscript; available in PMC: 2022 Aug 22.

Published in final edited form as: Br J Clin Pharmacol. 2020 Jul 5;87(2):622–631. doi: 10.1111/bcp.14429

Table 2. Haemoglobin results by exposure group.

	ACEI/ARB initiators (n=86,652)	CCB initiators (n=59,958)
Number of haemoglobin results (mean [SD])
Pre-initiation period	2.0 (2.1)	2.1 (2.3)
Post-initiation period	1.5 (1.2)	1.6 (1.3)
Haemoglobin level (g/dL) (mean [SD])
Pre-initiation	13.9 (1.7)	13.7 (1.7)
Post-initiation	13.6 (1.7)	13.5 (1.6)
Anaemia^a (n [%])
Pre-initiation (prevalence)	13,709 (15.8)	9,989 (16.7)
Post-initiation (incidence)^b	6,384 (8.8)	3,985 (8.0)

ACEI/ARB, ACE inhibitor / angiotensin receptor blocker; CCB, calcium channel blocker; SD, standard deviation.

Pre-initiation period: 12 months prior to drug initiation; post-initiation period: 6 months after drug initiation.

Haemoglobin <13g/dL in men or <12g/dL in women.

Incidence expressed as number (%) of new cases among patients that were not anaemic prior to drug initiation.